APOA1 and COVID-19: We used the “NAFLD-Serum” cohort to confirm the previous findings [9]: that before (Figure 14) and during (Figure 15) COVID-19, T2DM was associated with a decrease in ApoA1 compared with non-T2DM patients, in both in men and women.